The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.

The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.

Biogen pays up to $1B for secretive San Diego biotech RayThera, gaining three undisclosed anti-inflammatory candidates to expand in I&I.